Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 4, 1996, Pages 327-348

  Yamamoto, Koujirou ^a   Sawada, Yasufumi ^a,b   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cholinesterase inhibitor; In vitro in vivo relationship; Pharmacodynamics

Indexed keywords

ACETYLCHOLINE; AMBENONIUM; CHOLINESTERASE INHIBITOR; EDROPHONIUM; NEOSTIGMINE; NICOTINIC RECEPTOR; PYRIDOSTIGMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; ERYTHROCYTE; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE CONTRACTION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; STEADY STATE; THEORETICAL STUDY;

AMBENONIUM CHLORIDE; ANIMALS; CATTLE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDROPHONIUM; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; MUSCLE CONTRACTION; MYASTHENIA GRAVIS; NEOSTIGMINE; PYRIDOSTIGMINE BROMIDE; RATS; RATS, WISTAR; REGRESSION ANALYSIS; SCIATIC NERVE;

EID: 0030485704     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353516     Document Type: Article

References (57)

1. 14C-pyridostigmine in the rate. Br. J. Pharmacol. 26:393-402 (1966).
2. 14C-pyridostigmine in the rat. Br. J. Pharmacol. 34:445-450 (1968).
3. T. Taylor, D. R. Hawkins, T. J. Forrest, and H. Chung. Pharmacokinetics of pyridostigmine in dogs. J. Pharm. Sci. 80:353-356 (1991).
4. T. N. Calvey and K. Chan. Plasma pyridostigmine levels in patients with myasthenia gravis. Clin. Pharmacol. Ther. 21:187-193 (1977).
5. M. C. White, P. D. Silva, and C. W. H. Havard. Plasma pyridostigmine levels in myasthenia gravis. Neurology 31:145-150 (1981).
6. P. S. Sørensen, H. Flachs, M. L. Friis, E. F. Hvidberg, and O. B. Paulson. Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology 34:1020-1024 (1984).
7. S. L. Cohan, J. L. W. Pohlmann, J. Mikszewski, and D. S. O'Dohherty. The pharmacokinetics of pyridostigmine. Neurology 26:536-539 (1976).
8. U. Breyer-Pfaff, U. Maier, A. M. Brinkmann, and F. Schumm. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin. Pharmacol. Ther. 37:495-501 (1985).
9. S.-M. Aquilonius, S.-Å. Eckernäs, P. Hartvig, B. Lindström, and P. O. Osterman Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur. J. Clin. Pharmacol. 18:423-423 (1980).
10. S. L. Cohan, K. L. Dretchen, and A. Neal. Malabsorption of pyridostigmine in patients with myasthenia gravis. Neurology 27:299-301 (1977).
11. S. M. Somani, J. B. Roberts, and A. Wilson. Pyridostigmine metabolism in man. Clin. Pharmacol. Ther. 13:393-399 (1972).
12. L.-I. Hardess, B. Lindström, G. Lönnerholm, and R. O. Osterman. Pyridostigmine in human breast milk. Br. J. Clin. Pharmacol. 14:565-567 (1982).
13. J. B. Roberts, B. H. Thomas, and A. Wilson. Excretion of neostigmine labeled with carbon-14 in urine. Nature 200:1330 (1963).
14. 14C]-neostigmine in the rat and hen. Br. J. Pharmacol. 25:234-242 (1965).
15. 14C]-neostigmine in the rat. Br. J. Pharmacol. 25:763-770 (1965).
16. 14C-neostigmine in the rat. Biochem. Pharmacol. 15:71-75 (1966).
17. P. T. Nowell, C. A. Scott, and A. Wilson. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis. Br. J. Pharmacol. 18:617-624 (1962).
18. S.-M. Aquilonius, S.-Å. Eckernäs, P. Hartvig, J. Hultman, B. Lindström, and P. O. Osterman. Pharmacokinetic study of neostigmine in man using gas chromatographymass spectrometry. Eur. J. Clin. Pharmacol. 15:367-371 (1979).
19. 14C-edrophonium and its metabolites in bile: The role of the liver cell and the peribiliary vascular plexus. Br. J. Pharmacol. 44:534-543 (1972).
20. 14C-edrophonium from the circulation. Br. J. Pharmacol. 46:355-357 (1972).
21. H. E. Barber, T. N. Calvey, K. T. Muir, and K. Taylor. The effect of edrophonium on erythrocyte acetylcholinesterase and neuromuscular function in the rate. Br. J. Pharmacol. 56:93-99 (1976).
22. T. N. Calvey, N. E. Willians, K. T. Muir, and H. E. Barber. Plasma concentration of edrophonium in man. Clin. Pharmacol. Ther. 19:813-820 (1976).
23. S.-M. Aquilonius and P. Hartvig. Clinical pharmacokinetics of cholinesterase inhibitors. Clin. Pharmacokin. 11:236-249 (1986).
24. C. Tharasse-Bloch, C. Chabenat, P. Boucly, and J. Marchand. Determination of ambenonium chloride in serum by reversed-phase ion-pair liquid chromatography. J. Chromatog. 421:407-411 (1987).
25. K. Yamamoto, Y. Kohda, Y. Saitoh, and F. Nakagawa. Determination of ambenonium in biological samples by reversed-phase ion-pair liquid chromatography. J. Chromatog. 433:167-176 (1988).
26. K. Ohtsubo, S. Higuchi, and T. Aoyama. Sensitive determination of ambenonium chloride in serum from patients with myasthenia gravis using ion-exchange resin extraction and reversed-phase ion-pair chromatography. J. Chromatog. 496:397-406 (1989).
27. K. Yamamoto, Y. Sawada, and T. Iga. Sensitive determination of ambenonium in plasma using inhibitory activity to acetylcholinesterase. Biol. Pharm. Bull. 16:280-283 (1993).
28. K. Yamamoto, Y. Kohda, Y. Sawada, and T. Iga. Pharmacokinetics of ambenonium. a reversible cholinesterase inhibitor, in rats. Biopharm. Drug Dispos. 12:613-625 (1991).
29. C. Tharasse-Bloch, C. Chabenat, P. Boucly, F. Boismare, and J. Marchand. Pharmacokinetics of ambenonium chloride in dogs after intravenous and oral administration. Arzeneim. Forsch. 39:257-258 (1989).
30. C. Tharasse-Bloch, C. Chabenat, P. Boucly, J. Marchand, D. Elkharrat, C. Boucly-Goester, and P. Gajdos. Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis. Eur. J. Drug Metab. Pharmacokin. 16:299-303 (1991).
31. K. Ohtsubo, N. Fujii, S. Higuchi, T. Aoyama, I. Goto, and T. Tatsuhara. Influence of food on serum ambenonium concentration in patients with myasthenia gravis. Eur. J. Clin. Pharmacol. 42:371-374 (1992).
32. K. Chan and T. N. Calvey. Plasma concentration of pyridostigmine and effects in myasthenia gravis. Clin. Pharmacol. Ther. 22:596-601 (1978).
33. S. C. Davison, N. M. Hyman, A. Dehghan, and K. Chan. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis. J. Neurol. Neurosurg. Psychiat. 44:1141-1145 (1981).
34. S.-M. Aquilonius, S.-Å. Eckernäs, P. Hartvig, B. Lindström, and P. O. Osterman. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J. Neurol. Neurosurg. Psychiat. 46:929-935 (1983).
35. K. Yamamoto, Y. Sawada, and T. Iga. Appearance of tolerance in increase of contractile muscle tension by ambenonium in rats. Biol. Pharm. Bull. 17:944-947 (1994).
36. M. Kordas, M. Brzin, and Z. A. Majcen. A comparison of the effect of cholinesterase inhibitors on end-plate current and on cholinesterase activity in frog muscle. Neuropharmacoiogy 14:791-800 (1975).
37. N. T. Slater, M. Filbert, and D. O. Carpenter. Multiple interactions of anticholinesterases with Aplysia acetylcholine responses. Bruin Res. 375:407-412 (1986).
38. R. E. Wachtel. Comparison of anticholesterases and their effects on acetylcholine-activated ion channels. Anesthesiology 72:496-503 (1990).
39. G. J. Pascuzzo, A. Akaike, M. A. Maleque, K. P. Shaw, R. S. Aronstam, D. L. Rickett, and E. X. Albuquerque. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing, and binding properties. Mol. Pharmacol. 25:92-101 (1984).
40. M. G. M. De Ruyter and R. Cronnelly. Reversed-phase, ion-pair liquid chromatography of quaternary ammonium compounds. Determination of pyridostigmine, neostigmine and edrophonium in biological fluids. J. Chromatog. 183:193-201 (1980).
41. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 4:879-885 (1981).
42. K. Yamaoka and T. Nakagawa. A nonlinear least squares program based on differential equations, MULTI(RUNGE), for microcomputers. J. Pharmacobiodyn. 6:595-606 (1983).
43. S. A. Seifert and M. E. Eldefrawi. Affinity of myasthenia drugs to acetylcholinesterase and acetylcholine receptor. Biochem. Med. 10:258-265 (1974).
44. A. S. Hodge, D. R. Humphrey, and T. L. Rosenbery. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol. Pharmacol. 41:937-942 (1992).
45. A. F. Kopman. Pancuronium, gallamine, and d-tubocurarine compared: Is speed of onset inversely related to drug potency? Anesthesiology 70:915-920 (1989).
46. F. Donati and C. Meistelman. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J. Pharmacokin. Biopharm. 19:537-552 (1991).
47. J. C. L. Min, I. Bekavac, M. I. Glavinovic, F. Donati, and D. R. Bevan. Iontophoretic study of speed of action of various muscle relaxants. Anesthesiology 77:351-356 (1992).
48. M. I. Glavinovic, J. C. L. Min, L. Kapural, F. Donati, and D. R. Bevan. Speed of action of various muscle relaxants at the neuromuscular junction binding vs. buffering hypothesis. J. Pharmacol. Exp. Ther. 265:1181-1186 (1992).
49. T. P. Kenakin and D. Beek. Self-cancellation of drug properties as a mode of organ selectivity: The antimuscarinic effects of ambenonium. J. Pharmacol. Exp. Ther. 732-740 (1985).
50. C. J. Duncan and S. J. Publicover. Inhibitory effects of cholinergic agents on the release of transmitter at the frog neuromuscular junction. J. Physiol. 294:91-103 (1979).
51. R. J. Anderson. Effect of pyridostigmine on tetanic contracture of innervated and denervated rat skeletal muscle. Neurotoxicology 8:553-560 (1987).
52. M. Fujii and T. Namba. Inhibition of human motor endplate cholinesterase by anticholinesterase compounds. Acta Med. Okayama 36:229-232 (1982).
53. M. J. Chow, J. J. Ambre, T. I. Ruo, A. J. Atkinson, D. J. Bowsher, and M. W. Fischman. Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Ther. 38:318-324 (1985).
54. H. C. Porchet, N. L. Benowitz, and L. B. Sheiner. Pharmacodynamic model of tolerance: Application to nicotine. J. Pharmacol. Exp. Ther. 244:231-244 (1988).
55. M. M. Hammarlund, B. O. Odlind, and L. K. Paalzow. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 233:447-453 (1985).
56. D. Verotta, J. Kitts, R. Rodriguez, J. Coldwell, R. D. Miller, and L. B. Sheiner. Reversal of neuromuscular blockade in humans by neostigmine and edrophonium: A mathematical model. J. Pharmacokin. Biopharm. 19:713-729 (1991).
57. R. B. Morris, R. Cronnelly, R. D. Miller, D. R. Stanski, and M. R. Fahey. Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. Anesthesiology 54:399-402 (1981).